ProCE Banner Activity

AE Management With TROP-2 ADCs in NSCLC

Slideset

Download this slideset from a live symposium at ELCC 2024 for an expert overview of the adverse event profiles associated with the TROP-2 ADCs datopotamab deruxtecan and sacituzumab govitecan in advanced NSCLC, including similarities and differences along with guidance on their management.

Released: March 19, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.